Rheumatoid Arthritis (RA) Drugs Market 2017-2027

LONDON, November 10, 2017 /PRNewswire/ --

Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors

(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

- Do you need definitive Rheumatoid Arthritis market data? - Succinct Rheumatoid Arthritis market analysis? - Technological insight? - Clear competitor analysis? - Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time. 

The introduction of new biologic drugs in Rheumatoid Arthritis [https://www.visiongain.com/Report/2046/Rheumatoid-Arthritis-(RA)-Drugs-Market-2017-2027 ], has led Visiongain [https://www.visiongain.com ] to publish this timely report. The Rheumatoid Arthritis Drugs market [https://www.visiongain.com/Report/2046/Rheumatoid-Arthritis-(RA)-Drugs-Market-2017-2027 ] is expected to flourish in the next few years because of rise to prominence of biosimilars that provides a way of reducing the cost of treatment for patients. In addition, the arrival of new JAK inhibitors and BTK inhibitors could provide patients with oral treatments rather than taking their medications intravenously. The expected increases in efficacy are expected to feed through in the latter part of the decade driving growth to new heights. If you want to be part of this growing industry [https://www.visiongain.com/Report/2046/Rheumatoid-Arthritis-(RA)-Drugs-Market-2017-2027 ], then read on to discover how you can maximise your investment potential.

Report highlights 

- 135 quantitative tables, charts, and graphs across 183 pages 

- Analysis of key players in Rheumatoid Arthritis Market - AbbVie Pharmaceuticals - Roche Pharmaceuticals - Johnson & Johnson - Amgen - Pfizer - Merck and Co. - BMS - UCB

- Global Rheumatoid Arthritis market outlook and analysis from 2017-2027 

- Global Rheumatoid Arthritis Drugs forecasts and analysis from 2017-2027: 

- Major Biologics drugs forecast 2017-2027 - Major non-biologics drugs forecast 2017-2027 - Leading drugs forecast 2017-2027

- Regional Rheumatoid Arthritis market forecasts from 2017-2027: 

- US forecast 2017-2027, - Japan forecast 2017-2027 - India forecast 2017-2027 - Germany forecast 2017-2027 - UK forecast 2017-2027 - France forecast 2017-2027 - Italy forecast 2017-2027 - Spain forecast 2017-2027 - Brazil forecast 2017-2027 - Russia forecast 2017-2027 - China forecast 2017-2027

Key questions answered: 

- What does the future hold for the Pharmaceutical industry with regards to RA? - Where should you target your business strategy? - Which applications should you focus upon? - Which disruptive technologies should you invest in? - Which companies should you form strategic alliances with? - Which company is likely to success and why? - What business models should you adopt? - What industry trends should you be aware of?

Target audience: 

- Leading Pharmaceutical companies - Suppliers - Contractors - Technologists - R&D staff - Consultants - Analysts - CEO's - CIO's - COO's - Business development managers - Investors - Governments - Agencies - Banks

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com (+44-(0)-20-7336-6100) or refer to our website:

https://www.visiongain.com/Report/2046/Rheumatoid-Arthritis-(RA)-Drugs-Market-2017-2027

Companies Mentioned in the Report 

Abbvie

Ablynx

Abott Laboratories

Alder

Amgen

Astellas

Baxalta

Biocad

Biocon

Biogen

Bioxpress Therapeutics

BMS

Boehringer Ingelheim

Can-Fite

Celtrion

Chugai Pharmaceutical Co Ltd.

Cipla

Coherus Biosciences Inc

Covagen AG

Daiichi Sankyo

Dr Reddy's Laboratories

Eli Lilly

Epirus

Fujifilm Kyowa Kirin

Galapagos

Genentech

Gilead Sciences Inc

GSK

Hanmi

Hanwha Chemical

Hetero Group

Hospira

IMS Health

Incyte

Intas

Janseen Biologics

Johnson and Johnson

LG Life Sciences

Merk

Mitshubisi

Momenta

MorphoSys

Mycenax Biotech

Mylan

Nichi-lko

Novartis

Oncobiologics

Pfenex

Pfizer

Protalix Biotherapeutics

Regeneron

Roche

Samsung Bioepis

Sanofi

Shanghai Celgen

Shanghai CP Goujian Pharmaceutical Co

Sharp & Dhome

Simcere Pharmaceuticals

Sun Pharma

Takeda

Tanabe Pharma

Torrent Pharmaceuticals

TSH Biopharm

UCB

Van der Heijde

Vitaeris

Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

    Photo: 
    http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain